| A Study to Investigate the Effect of Roxadustat Versus Recombinant Human Erythropoietin (rHuEPO) on Oral Iron Absorption in Chinese Patients With Anemia of Chronic Kidney Disease (CKD) (NCT04655027) | AstraZeneca | 2021-02-22 |
| AZD4573 in Novel Combinations With Anti-cancer Agents in Patients With Advanced Blood Cancer (NCT04630756) | AstraZeneca | 2021-02-17 |
| ALICIA (Acalabrutinib in CLL Therapy) (NCT04746950) | AstraZeneca | 2021-02-03 |
| Phase 1b Study of Dato-DXd in Combination With Immunotherapy With or Without Carboplatin in Advanced or Metastatic Non-Small Cell Lung Cancer (NCT04612751) | AstraZeneca | 2021-02-02 |
| 'OLAP' (OLAparib Regulatory Post-marketing Surveillance) (NCT04553926) | AstraZeneca | 2021-02-01 |
| A Study to Assess How Itraconazole Affects the Uptake and Elimination of Capivasertib in the Body (NCT04712396) | AstraZeneca | 2021-02-01 |
| Study to Assess Relative Bioavailability and Safety of AZD5718 in Healthy Volunteers (NCT04734275) | AstraZeneca | 2021-02-01 |
| Post-Authorisation Safety Study of Lesinurad (NCT04072471) | AstraZeneca | 2021-01-29 |
| Phase III Study of AZD7442 for Treatment of COVID-19 in Outpatient Adults (NCT04723394) | AstraZeneca | 2021-01-28 |
| A Comparative Study of AZD9833 Plus Palbociclib Versus Anastrozole Plus Palbociclib in Patients With ER-Positive HER2 Negative Breast Cancer Who Have Not Received Any Systemic Treatment for Advanced Disease (NCT04711252) | AstraZeneca | 2021-01-28 |
| A Study of Neoadjuvant Hormone Therapy in Patient With Advanced Prostate Cancer Undergoing Radical Prostatectomy. (NCT03971110) | AstraZeneca | 2021-01-28 |
| Efficacy, Safety and Tolerability of AZD9977 and Dapagliflozin in Participants With Heart Failure and Chronic Kidney Disease (NCT04595370) | AstraZeneca | 2021-01-26 |
| A Study of AZD8233 in Participants With Dyslipidemia. (NCT04823611) | AstraZeneca | 2021-01-20 |
| Study to Evaluate the Pharmacokinetics of CIN-107 in Subjects With Varying Degrees of Renal Function (NCT05470725) | AstraZeneca | 2021-01-12 |
| Olaparib Real-world Utilization and Clinical Outcomes in France, Italy, and the UK (NCT04532645) | AstraZeneca | 2021-01-07 |
| A Study of T-DXd for the Treatment of Solid Tumors Harboring HER2 Activating Mutations (NCT04639219) | AstraZeneca | 2020-12-30 |
| A Phase 1b/2 Study of T-DXd Combinations in HER2-positive Metastatic Breast Cancer (NCT04538742) | AstraZeneca | 2020-12-28 |
| Dapagliflozin Effects on Cardiometabolic Outcomes in Patients With an Acute Heart Attack. (NCT04564742) | AstraZeneca | 2020-12-22 |
| Heart Failure Patients Registry (NCT04709263) | AstraZeneca | 2020-12-21 |
| A Phase 1b Study of T-DXd Combinations in HER2-low Advanced or Metastatic Breast Cancer (NCT04556773) | AstraZeneca | 2020-12-17 |
| A Study of Selumetinib in Chinese Paediatric and Adult Subjects With Neurofibromatosis Type 1 (NF1) and Inoperable Plexiform Neurofibromas (PN) (NCT04590235) | AstraZeneca | 2020-12-16 |
| A Study of Osimertinib With or Without Chemotherapy Versus Chemotherapy Alone as Neoadjuvant Therapy for Patients With EGFRm Positive Resectable Non-Small Cell Lung Cancer (NCT04351555) | AstraZeneca | 2020-12-16 |
| Durvalumab Plus Chemotherapy in Untreated Patients With Extensive-Stage Small Cell Lung Cancer (NCT04712903) | AstraZeneca | 2020-12-16 |
| Study to Assess PT010 in Adult and Adolescent Participants With Inadequately Controlled Asthma (KALOS) (NCT04609878) | AstraZeneca | 2020-12-15 |
| A Phase II, Randomized, Double-blind, Placebo-controlled Study to Assess MEDI3506 in Participants With COPD and Chronic Bronchitis (NCT04631016) | AstraZeneca | 2020-12-14 |
| Durvalumab Plus Chemotherapy in ES-SCLC (Oriental) (NCT04449861) | AstraZeneca | 2020-12-07 |
| Phase III Double-blind, Placebo-controlled Study of AZD7442 for Post- Exposure Prophylaxis of COVID-19 in Adults (NCT04625972) | AstraZeneca | 2020-12-02 |
| A Study of the Efficacy and Safety of MEDI7352 in Participants With Painful Osteoarthritis of the Knee (NCT04675034) | AstraZeneca | 2020-12-02 |
| A Study Investigating DNA-damage Response Agents in Molecularly Altered Advanced Cancer (NCT04564027) | AstraZeneca | 2020-12-01 |
| Study of Relationship Between Changes in Inflammation, Lung Function, Symptoms and Medication Use in COPD Patients (NCT04168216) | AstraZeneca | 2020-11-30 |
| A Study of Adavosertib as Treatment for Uterine Serous Carcinoma (NCT04590248) | AstraZeneca | 2020-11-30 |
| Study of Durvalumab Following Radiation Therapy in Patients With Stage 3 Unresectable NSCLC Ineligible for Chemotherapy (NCT04249362) | AstraZeneca | 2020-11-26 |
| AMAZE™ Asthma Implementation QI Study (NCT04901260) | AstraZeneca | 2020-11-25 |
| Phase III Double-blind, Placebo-controlled Study of AZD7442 for Pre-exposure Prophylaxis of COVID-19 in Adult. (NCT04625725) | AstraZeneca | 2020-11-21 |
| Assessment of Safety, Tolerability, Immunogenicity, and Pharmacokinetics of AZD3427 (NCT04630067) | AstraZeneca | 2020-11-17 |
| Assessing Durvalumab and FLOT Chemotherapy in Resectable Gastric and Gastroesophageal Junction Cancer (NCT04592913) | AstraZeneca | 2020-11-17 |
| Reduce Incidence of Pre-Dialysis Hyperkalaemia With Sodium Zirconium Cyclosilicate in Chinese Subjects (NCT04217590) | AstraZeneca | 2020-11-16 |
| Absolute Bioavailability and ADME Study of Savolitinib in Healthy Male Subjects (NCT04675021) | AstraZeneca | 2020-11-13 |
| Efficacy and Safety Study of the Use of Benralizumab for Patients With Moderate to Severe Atopic Dermatitis (NCT04605094) | AstraZeneca | 2020-11-12 |
| Study of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies (NCT04644068) | AstraZeneca | 2020-11-12 |
| A Study to Assess Safety, Tolerability, PK and PD of AZD2693 in Non-alcoholic Steatohepatitis Patients (NCT04483947) | AstraZeneca | 2020-11-06 |
| Efficacy and Safety of MEDI6570 in Patients With a History of Myocardial Infarction (NCT04610892) | AstraZeneca | 2020-11-04 |
| A Study to Investigate the Biological Effects of AZD9833 in Women With ER-positive, HER2 Negative Primary Breast Cancer (NCT04588298) | AstraZeneca | 2020-11-02 |
| Study to Evaluate the Effect of CIN-107 on the Pharmacokinetics of the MATE Substrate, Metformin, in Healthy Subjects (NCT05526690) | AstraZeneca | 2020-10-28 |
| A Study of AZD8233 in Participants With Dyslipidemia (NCT04641299) | AstraZeneca | 2020-10-28 |
| A Study to Investigate the Use of Benralizumab in Patients With Chronic Spontaneous Urticaria Who Are Symptomatic Despite the Use of Antihistamines (ARROYO) (NCT04612725) | AstraZeneca | 2020-10-27 |
| Patient Palatability and Preference of 3 Potassium Binders in Patients With Chronic Kidney Disease and Hyperkalaemia (NCT04566653) | AstraZeneca | 2020-10-23 |
| Determination of Prevalence and Features of HRRm mCRPC (ADAM) (NCT04712890) | AstraZeneca | 2020-10-23 |
| A Study to Assess Drug Absorption of Fixed Dose Combinations of Budesonide, Glycopyrronium, and Formoterol (NCT04600505) | AstraZeneca | 2020-10-19 |
| Study of Durvalumab Versus Placebo in Combination With Definitive Chemoradiation Therapy in Patient With ESCC (NCT04550260) | AstraZeneca | 2020-10-19 |
| Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of AZD3366 in Healthy Subjects, Japanese and Chinese Subjects (NCT04588727) | AstraZeneca | 2020-10-15 |
| A Study in Healthy Subjects to Assess Bioavailability (Proportion of a Drug Which Enters the Circulation to Have an Active Effect) of Acalabrutinib Tablet and Protonpump Inhibitor Effect (Members of a Class of Medications That Inhibits in Gastric Acid Production) for Rabeprazole (NCT04564040) | AstraZeneca | 2020-10-12 |
| Assessment of Efficacy and Safety of Monalizumab Plus Cetuximab Compared to Placebo Plus Cetuximab in Recurrent or Metastatic Head and Neck Cancer (NCT04590963) | AstraZeneca | 2020-10-02 |
| A Study to Evaluate the Safety and Efficacy of AZD5718 in Participants With Proteinuric Chronic Kidney Disease (NCT04492722) | AstraZeneca | 2020-10-01 |
| A Phase 1 Study of AZD9833 in Japanese Women With ER Positive, HER2 Negative Advanced Breast Cancer (NCT04541433) | AstraZeneca | 2020-09-29 |
| A Study Comparing Savolitinib Plus Osimertinib vs Savolitinib Plus Placebo in Patients With EGFRm+ and MET Amplified Advanced NSCLC (NCT04606771) | AstraZeneca | 2020-09-28 |
| Patient Characteristics, Persistence to Treatment and Outcome Events in Patients Treated With Ticagrelor 60 mg After Myocardial Infarction in Real-world Clinical Practice (NCT04568083) | AstraZeneca | 2020-09-25 |
| A Study of Benralizumab in Patients With Eosinophilic Esophagitis (NCT04543409) | AstraZeneca | 2020-09-22 |
| Evaluate the Safety of Linaclotide in IBS-C Patients in China (NCT04462900) | AstraZeneca | 2020-09-18 |
| Study to Assess the Efficacy and Safety of MEDI3506 in Adults With Uncontrolled Moderate-to-severe Asthma (NCT04570657) | AstraZeneca | 2020-09-17 |
| A Study to Assess the Rel Bioavailability, Food Effect and Absolute Bioavailability on the Pharmacokinetics of AZD9833 (NCT04546347) | AstraZeneca | 2020-09-17 |
| Pharmacokinetics of Verinurad and Allopurinol in Combination With Cyclosporine and Rifampicin in Healthy Volunteers (NCT04532918) | AstraZeneca | 2020-09-10 |
| AZD1222 Vaccine for the Prevention of COVID-19 (NCT04540393) | AstraZeneca | 2020-09-02 |
| A Study of Cotadutide in Participants Who Have Chronic Kidney Disease With Type 2 Diabetes Mellitus (NCT04515849) | AstraZeneca | 2020-08-31 |
| Selumetinib Paediatric NF1 Japan Study (NCT04495127) | AstraZeneca | 2020-08-31 |
| Phase III Double-blind, Placebo-controlled Study of AZD1222 for the Prevention of COVID-19 in Adults (NCT04516746) | AstraZeneca | 2020-08-28 |
| Study of AZD1222 for the Prevention of COVID-19 in Japan (NCT04568031) | AstraZeneca | 2020-08-23 |
| Evaluate the Safety and Tolerability, for Nirsevimab in Immunocompromised Children (NCT04484935) | AstraZeneca | 2020-08-19 |
| First Time in Human Study of AZD8701 With or Without Durvalumab in Participants With Advanced Solid Tumours (NCT04504669) | AstraZeneca | 2020-08-18 |
| AZD7442 - a Potential Combination Therapy for the Prevention and Treatment of COVID-19 (NCT04507256) | AstraZeneca | 2020-08-18 |
| A Phase 2 Study of T-DXd in Patients With Selected HER2 Expressing Tumors (NCT04482309) | AstraZeneca | 2020-08-18 |
| A Study to Evaluate the Effectiveness and Tolerability of a Second Maintenance Treatment in Participants With Ovarian Cancer, Who Have Previously Received Polyadenosine 5'Diphosphoribose [Poly (ADP Ribose)] Polymerase Inhibitor (PARPi) Treatment. (NCT04239014) | AstraZeneca | 2020-08-07 |
| Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With Olaparib (NCT04421963) | AstraZeneca | 2020-08-04 |
| Multiple Ascending Dose Study of MEDI1341 in Patients With Parkinson's Disease (NCT04449484) | AstraZeneca | 2020-08-04 |
| A Study of AZD4635 With Durvalumab and With Cabazitaxel and Durvalumab in Patients With mCRPC. (NCT04495179) | AstraZeneca | 2020-08-04 |
| Assessment of Hyperkalemia's Illness and Treatment Burden in Chronic Kidney Disease and Heart Failure Patients: HK Registry Pilot Study (NCT04466969) | AstraZeneca | 2020-07-31 |
| A Study to Assess the Effect of Multiple Doses of AZD5718 on Pharmacokinetics of Oral Midazolam in Healthy Subjects (NCT04492709) | AstraZeneca | 2020-07-30 |
| Prevalence of HRR-related Genes Mutations and Prognosis in Metastatic Castration Resistant Prostate Cancer (mCRPC) Patients in Real World Setting (NCT04425200) | AstraZeneca | 2020-07-29 |
| A Study to Assess the Reduction of Daily Maintenance ICS/LABA Treatment Towards Anti-Inflammatory Reliever Treatment in Patients With Severe Eosinophilic Asthma Treated With Benralizumab (NCT04159519) | AstraZeneca | 2020-07-27 |
| Study of Trastuzumab Deruxtecan (T-DXd) vs Investigator's Choice Chemotherapy in HER2-low, Hormone Receptor Positive, Metastatic Breast Cancer (NCT04494425) | AstraZeneca | 2020-07-24 |
| A Study to Evaluate the Safety and Pharmacokinetics With MEDI8367 Administered in Healthy Subjects, and in Subjects With Chronic Kidney Disease (NCT04365218) | AstraZeneca | 2020-07-22 |
| A Study to Assess the Effect of Fluvoxamine and Smoking on Pharmacokinetics ( the Movement of Drugs Within the Body) of AZD4635 in Healthy Volunteers (NCT04478513) | AstraZeneca | 2020-07-21 |
| HF Prevalence and Evolution of HF in DM II Patients at High Risk (NCT04482283) | AstraZeneca | 2020-07-20 |
| A Study to Evaluate Effects of Proton-pump Inhibitor on Acalabrutinib Capsule When Administered Orally With COCA-COLA in Healthy Participants (NCT04489797) | AstraZeneca | 2020-07-20 |
| A Phase III Study to Evaluate the Efficacy and Safety of Benralizumab in Patients With Hypereosinophilic Syndrome (HES) (NCT04191304) | AstraZeneca | 2020-07-20 |
| Evaluation of AZD8154 Concentrations in Blood (NCT04480879) | AstraZeneca | 2020-07-17 |
| Phase III Study to Determine the Efficacy of Durvalumab in Combination With Chemotherapy in Completely Resected Stage II-III Non-small Cell Lung Cancer (NSCLC) (NCT04385368) | AstraZeneca | 2020-07-17 |
| Capivasertib+Abiraterone as Treatment for Patients With Metastatic Hormone-sensitive Prostate Cancer and PTEN Deficiency (NCT04493853) | AstraZeneca | 2020-07-13 |
| Study to Evaluate the Effect of Ticagrelor Versus Placebo in Reducing Vaso-Occlusive Crises Rate in Pediatric Patients With Sickle Cell Disease. (NCT04293172) | AstraZeneca | 2020-06-30 |
| Study of Exenatide Once-Weekly Suspension in Chinese Patients With Type 2 Diabetes Mellitus (NCT04001231) | AstraZeneca | 2020-06-30 |
| A Study to Assess the Mass Balance Recovery, Pharmacokinetics, Metabolite Profile and Metabolite Identification of [14C]AZD4831 (NCT04407091) | AstraZeneca | 2020-06-30 |
| An INternational Frontline Ovarian Cancer Real World Management Study (NCT04460768) | AstraZeneca | 2020-06-27 |
| Study of Adavosertib(AZD1775) in Japanese Patients With Advanced Solid Tumours (NCT04462952) | AstraZeneca | 2020-06-24 |
| A Study to Evaluate Relative Bioavailability, Proton Pump Inhibitor (PPI) (Rabeprazole) Effect, Food Effect and Particle Size Effect of New Acalabrutinib Tablet in Healthy Subjects (NCT04488016) | AstraZeneca | 2020-06-24 |
| Study to Assess the Pharmacokinetics and Safety of AZD9977 in Participants With Renal Impairment (NCT04469907) | AstraZeneca | 2020-06-22 |
| Acalabrutinib Study With Best Supportive Care Versus Best Supportive Care in Subjects Hospitalized With COVID-19. (NCT04380688) | AstraZeneca | 2020-06-13 |
| Real-world Data on Stage III NSCLC Patients Treated With Durvalumab After Chemoradiotherapy in Asia Area (PACIFIC AA) (NCT04529564) | AstraZeneca | 2020-06-12 |
| Ph1b/2 Study of the Safety and Efficacy of T-DXd Combinations in Advanced HER2-expressing Gastric Cancer (DESTINY-Gastric03) (NCT04379596) | AstraZeneca | 2020-06-03 |
| Prospective Multicentre Phase-IV Clinical Trial of Olaparib in Indian Patients With Ovarian and Metastatic Breast Cancer (NCT04330040) | AstraZeneca | 2020-05-25 |
| A Study of Acalabrutinib Suspension to Evaluate Relative Bioavailability and Proton-pump Inhibitor Effect in Healthy Volunteers (NCT04435483) | AstraZeneca | 2020-05-22 |